EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Quality of Life in CAR-T Cell Therapy

Caterina Alati, Martina Pitea iD, Gaetana Porto, Giorgia Policastro, Erica Bilardi iD, Giovanna Utano, Laura Giordano, Annalisa Sgarlata, Ilaria Maria Delfino iD, Aurora Idato, Giulia Santoro, Filippo Antonio Canale iD und 2 weitere

Hematology Reports · 10.06.2026 · 18 (3) · 40

DOI: 10.3390/hematolrep18030040 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematology Reports, online erschienen am 10.06.2026. Verfasst von Caterina Alati und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropol…. Die Arbeit nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of relapsed or refractory hematologic malignancies, achieving high response rates in B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and multiple myeloma. While the efficacy of CAR-T therapy is well established, quality of life (QoL) metrics have become increasingly important for guiding treatment decisions, patient counseling, and survivorship planning.

Objectives

Most patients undergoing CAR-T therapy recover their initial QoL within 3 months, an improvement not typically seen with other treatment options. A comprehensive understanding of QoL is essential for delivering patient-centered care in the evolving CAR-T landscape.

Conclusions

This review synthesizes current evidence on QoL outcomes in CAR-T recipients, including acute effects, recovery trajectories, comparisons with conventional therapies, and strategies to optimize QoL.

Schlagwörter

Stichwörter der Autor:innen

CAR-TQoLhematologic malignancies

Autor:innen und Institutionen

  • Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", 89133 Reggio Calabria, Italy.
  • Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Bio Medico, 00128 Rome, Italy.

ORCID-Profile: Martina Pitea, Erica Bilardi, Ilaria Maria Delfino, Filippo Antonio Canale, Massimo Martino

Zitieren

APA

Alati, C., Pitea, M., Porto, G., Policastro, G., Bilardi, E., Utano, G., Giordano, L., Sgarlata, A., Delfino, I. M., Idato, A., Santoro, G., Canale, F. A., Naso, V., & Martino, M. (2026). Quality of Life in CAR-T Cell Therapy. Hematology Reports, 18(3), 40. https://doi.org/10.3390/hematolrep18030040

Vancouver

Alati C, Pitea M, Porto G, Policastro G, Bilardi E, Utano G, et al. Quality of Life in CAR-T Cell Therapy. Hematology Reports. 2026;18(3):40. doi:10.3390/hematolrep18030040

BibTeX
@article{Alati2026,
  author = {Alati, Caterina and Pitea, Martina and Porto, Gaetana and Policastro, Giorgia and Bilardi, Erica and Utano, Giovanna and Giordano, Laura and Sgarlata, Annalisa and Delfino, Ilaria Maria and Idato, Aurora and Santoro, Giulia and Canale, Filippo Antonio and Naso, Virginia and Martino, Massimo},
  title = {Quality of Life in CAR-T Cell Therapy},
  journal = {Hematology Reports},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {40},
  doi = {10.3390/hematolrep18030040}
}
Kostenlos starten →